Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul;103(7):e304-e306.
doi: 10.3324/haematol.2017.183350. Epub 2018 Mar 15.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia

Pierre Feugier  1 , Thérèse Aurran  2 , Béatrice Mahé  3 , Remi Letestu  4 , Florence Nguyen-Khac  5 , Bruno Cazin  6 , Olivier Tournilhac  7 , Hervé Maisonneuve  8 , Olivier Casasnovas  9 , Alain Delmer  10 , Véronique Leblond  11 , Bruno Royer  12 , Bernadette Corront  13 , Sylvie Chevret  14 , Roselyne Delépine  15 , Sandrine Vaudaux  16 , Eric Van Den Neste  17 , Marie-Christine Béné  3 , Florence Cymbalista  4 , Damien Ross-Weil  11 , Stéphane Leprêtre  16
Affiliations

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia

Pierre Feugier et al. Haematologica. 2018 Jul.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Long-term progression-free survival survival (PFS) in the FCCam (dashed line) and FCR (solid line) arms of the study. PFS was estimated for the FCCam and FCR arms by the nonparametric Kaplan-Meier method and compared by log-rank test.
Figure 2.
Figure 2.
Overall survival (OS) and progression-free survival (PFS) according to the presence of minimal residual disease (MRD) in the peripheral blood at month 9. PFS and OS were estimated for patients negative (MRD neg: solid line) and positive (MRD pos: dashed line) for MRD at month 9 (i.e. 3 months after treatment completion) by the non-parametric Kaplan-Meier method and compared by log-rank test.
See this image and copyright information in PMC

References

    1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174. - PubMed
    1. Skarbnik AP, Faderl S. The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies. Ther Adv Hematol. 2017;8(3):99–105. - PMC - PubMed
    1. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616–5623. - PubMed
    1. Lepretre S, Aurran T, Mahe B, et al. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. Blood. 2012;119(22):5104–5110. - PubMed
    1. Montillo M, Tedeschi A, Belsito Petrizzi V, et al. An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia. Blood. 2011;118(15):4079–4086. - PubMed

Publication types

MeSH terms

LinkOut - more resources